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ABSTRACT
Timely diagnosis of hereditary variant transthyretin (ATTRv) amyloidosis is critical for appropriate treatment
and optimal outcomes. Significant differences are seen between patients receiving treatment and those
who are not, though disease progression may continue despite treatment in some patients. Healthcare
professionals caring for patients with ATTRv amyloidosis therefore need reliable ongoing assessments to
understand the continuing course of disease and make appropriate treatment choices on an individual
basis. Various signs and symptoms experienced by patients may be evaluated as indicators of disease pro-
gression, though there is currently no validated score that can be used for such ongoing assessment.
Recognizing this situation, a group of clinicians highly experienced in ATTR amyloidosis developed an
approach to understand and define disease progression in diagnosed and treated patients with ATTRv
amyloidosis. The suggested approach is based on the recognition of distinct phenotypes which may use-
fully inform the particular tools, tests and investigations that are most likely to be appropriate for individ-
ual patients. It is aimed at implementing appropriate and ongoing assessment of patients being treated
for ATTRv amyloidosis, such that the effectiveness of management can be usefully assessed throughout
the course of disease and management can be tailored according to the patient’s requirements.
Abbreviations: 6MWT: 6-minute walk test; ATTR-CM: hereditary transthyretin amyloid cardiomyopathy;
ATTR-PN: hereditary transthyretin amyloid polyneuropathy; ATTRv: variant transthyretin amyloidosis;
BMI: body mass index; CMAP: compound muscle action potentials; CMR: cardiac magnetic resonance;
COMPASS-31: Composite Autonomic Symptom Score 31; ECG: electrocardiography; ECV: extracellular
volume; EMG: electromyography; ESC: electrochemical skin conductance; FAP-RODS: Familial Amyloid
Polyneuropathy Specific Rasch-Built Overall Disability Scale; IVCM: In vivo confocal microscopy; LEP:
laser-evoked potentials; LV: left ventricular; mNIS þ 7: Modified Neuropathy Impairment Score þ7;
NCS: nerve conduction studies; NDS: Neurologic Disability Score; NIS: Neuropathy Impairment Score;
NIS-LL: Neuropathy Impairment Score in the lower limbs; Norfolk QoL-DN: Norfolk Quality of Life-
Diabetic Neuropathy; NT-proBNP: N-terminal pro-brain natriuretic peptide; NYHA: New York Heart
Association; PND: polyneuropathy disability; PSMS: Physical Self-Maintenance Scale; QSART: quantita-
tive sudomotor axon reflex test; QST: quantitative sensory testing; SNAP: sensory nerve action poten-
tials; SSR: sympathetic skin response; TTR: transthyretin
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Hereditary variant transthyretin (ATTRv) amyloidosis is a
rare and devastating disease resulting from extracellular
deposition of amyloid fibrils formed by transthyretin (TTR),
a transport protein produced predominantly by the liver
[1,2]. It is an autosomal dominant disorder with an age of
onset ranging from the second to the ninth decade of life
and various clinical manifestations including progressive
sensorimotor and autonomic neuropathy (hereditary ATTR
polyneuropathy [ATTR-PN]), infiltrative cardiomyopathy
(hereditary ATTR cardiomyopathy [ATTR-CM]) [2,3], amyl-
oid ophthalmopathy [4] and nephropathy [1,5]. More than
130 different TTR gene mutations associated with the disease
have been identified worldwide, of which Val30Met has been
the most commonly recognized to date [5].
Diagnosis of ATTRv amyloidosis is often challenging,
particularly due to low awareness or understandable lack
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of suspicion in patients presenting in the general medical
system and with no known family history of the disease.
Timely diagnosis is, however, critical for appropriate treat-
ment and optimal outcomes [5]. A diagnosis of active dis-
ease in individuals with a TTR gene mutation should be
made in the presence of at least one quantified or objective
symptom or sign definitively related to the onset of symp-
tomatic ATTRv amyloidosis; or at least one probably related
symptom plus one abnormal definitive or confirmed test
result; or two abnormal definitive or confirmed test results
in the absence of clinical symptoms [6].
Data from registries of diagnosed and treated patients,
such as the Transthyretin Amyloidosis Outcomes Survey
(THAOS), indicate that disease progression may variably
continue despite appropriate treatment, although treatment
has been shown to slow disease progression [7]. This situ-
ation demands accurate and structured monitoring of the
ongoing and changing disease state in individual patients.
An understanding of the disease course will help to
inform decisions on important components of physiological,
pharmacological or psychological management, as well as
other essential aspects of supportive care.
Various signs and symptoms experienced by patients have
significant potential as ongoing indicators of disease progres-
sion. These include unintentional and continuous weight loss;
new appearance or worsening of autonomic problems, such
as impotence, diarrhoea or orthostatic hypotension; progres-
sion of somatic neuropathy (sensory and motor); develop-
ment/progression of ocular complications (vitreous opacities/
secondary glaucoma); and development/progression of car-
diac manifestations.
A group of clinicians experienced in the care of people
diagnosed with ATTR amyloidosis met to develop an
approach to understanding and defining disease progres-
sion in diagnosed and treated patients with ATTRv amyl-
oidosis. This multidisciplinary group included neurologists,
an ophthalmologist and cardiologist and internal medicine
specialists.
This publication aims to outline the suggested structured
approaches agreed by the group, to help in the ongoing
assessment of individual patients being treated for ATTRv
amyloidosis, to better understand changes in the disease,
provide a personalized approach for monitoring of disease
and optimize patient care and management.
Methods
In July 2017, a dedicated team of experts in ATTR amyloidosis
met to discuss the ongoing management of patients with
ATTRv amyloidosis. Based on literature review, analysis of
the methodologies utilized in clinical trials investigating the
treatment of ATTRv amyloidosis and the experts’ personal
knowledge from years of real-world experience, the group
aimed to identify the tests and investigations that best evaluate
disease progression in diagnosed and treated patients and
achieve consensus on the clinical indicators and thresholds
that define disease progression and indicate a need for change
in the management of such patients.
Initial monitoring considerations – diagnostic tests may
not be appropriate in the treatment phase
Once a person has been diagnosed and is being treated for
confirmed ATTRv amyloidosis, it is important to employ
tests and assessments that are capable of revealing ongoing
change rather than the existence of the disease state itself, as
in the initial diagnostic work-up. Tests undertaken as part
of the diagnostic process may therefore not be as useful in
the long-term monitoring of the changing state of ATTRv
amyloidosis. Indeed, tests and investigations that are useful
for the initial diagnosis of the disease may have a “floor” or
“ceiling” effect, whereby no further change in the parameter
being measured occurs due to ongoing disease progression.
This means that such useful diagnostic tests may have lim-
ited utility in assessing subsequent treatment outcomes or in
identifying ongoing disease progression.
As an example, long-term follow-up of patients in clinical
trials has shown that both change from baseline and ongoing
change in the Neuropathy Impairment Score (NIS, especially
in the lower limbs [NIS-LL]) have been a useful parameter
for measuring early disease progression in the study setting
[8,9]. However, it is acknowledged that this measure may
have a rapid “ceiling” effect, particularly in sensory evalua-
tions and may not be useful after the stages of early disease
progression. The Modified Neuropathy Impairment Score
þ7 (mNIS þ 7) may be a more useful measure for ongoing
assessment [10], although it is accepted that this measure is
complex and time-consuming in real-life clinical practice,
often involving a degree of training and central laboratory
reference values in order to be used appropriately [11].
Designing a specific approach to follow-up treated
patients with ATTRv amyloidosis
ATTRv amyloidosis presents with many different clinical pre-
sentations and with considerable variation in terms of signs
and symptoms, among individuals and across geographic loca-
tions [2]. There are also important differences in TTR gene
mutations, which, in turn, are associated with different pheno-
types [2]. Even for a specific TTR gene mutation, phenotypes
may be polymorphous, even within the same family [2]. In
addition, late-onset disease may be different from early-onset
disease, in terms of amyloid deposition and disease course [2].
The different phenotypes seen in clinical practice (and
largely associated with TTR gene mutation or time of disease
onset) could lead to the definition of four major phenotype
groups: Val30Met early onset (<50 years); Val30Met late
onset (>50 years); non-Val30Met mixed phenotype and non-
Val30Met cardiac phenotype (eg Val122Ile) [6] (Table 1).
Recognition of these groups usefully informs the particular
tools, tests and investigations that are most relevant to the
long-term follow-up of specific patients. Clinical approaches
will also need to address change in the individual patient as
the disease progresses and specific dysfunctions or disabilities
become the key impact on the individual.
It should be noted that the exact age of disease onset
may be difficult to determine with certainty and an alterna-
tive approach to differentiate between the two phenotypes
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of Val30Met patients has previously been reported, which
is based on the amyloid fibril composition (Type A or Type
B) [12]. However, as not every centre diagnosing patients
has the expertise or resources to perform fibril typing, we
have categorized disease according to age of onset, which is
currently more widely used.
Which tests and investigations will be most useful for
the ongoing monitoring of treated patients with ATTRv
amyloidosis?
After review of the published literature and the approach
applied when assessing symptoms of disease and its progres-
sion in clinical trials [8,9,11,13–17], it was agreed that tests
should be targeted at the expected phenotypical presentation
for the specific mutation. For all tests, it is important to
establish baseline values and repeatability of the different
measurements in order to assess ongoing change in routine
follow-up.
Below, we outline the proposed tests and assessments
that should be applied to monitor disease progression in
treated patients with ATTRv amyloidosis.
Patient-reported aspects and quality of life measures
Patient-reported aspects are an essential component of
understanding disease progression and its impact on daily
living in the individual being assessed. Information on
patient-reported symptoms (neuropathic [positive and/or
negative], gastrointestinal, genitourinary, sexual dysfunc-
tion, severe syncope) should be collected and compared
every 6months.
Patient questionnaires can be used to measure changes
in health-related quality of life. The Norfolk Quality of Life-
Diabetic Neuropathy (Norfolk QoL-DN) questionnaire is
a 35-item, self-reported questionnaire to assess patients’
subjective perceptions of symptoms associated with specific
nerve fibre damage. The questionnaire comprises domains
for physical functioning/large-fibre neuropathy, symptoms,
activities of daily life, small-fibre neuropathy and autonomic
neuropathy and has been validated for use in patients with
ATTRv amyloidosis as a reliable indicator of disease severity
[9,16,18,19]. Indeed, in some countries, the patient’s Norfolk
QoL-DN score must be provided to the regulatory authorities
during treatment with approved drugs.
Additionally, the Val30Met Familial Amyloid
Polyneuropathy Specific Rasch-Built Overall Disability Scale
(FAP-RODS) is a 34-item, disease-specific interval measure
suitable for detecting activity and participation restrictions
in patients with ATTRv amyloidosis [20].
The Composite Autonomic Symptom Score 31
(COMPASS-31) is another useful self-reported questionnaire
designed to comprehensively evaluate the severity and distri-
bution of symptoms and the autonomic functional capacity
of patients with autonomic disorders. It has good psycho-
metric properties in the population of patients being eval-
uated for small-fibre polyneuropathy [21].
For general functioning, various scales are available for
assessing activities of daily living. These include the Physical
Self-Maintenance Scale (PSMS), the Katz ADL Index and
the Barthel ADL Index [22]. These can be used regularly to
detect any changes or the emergence of new symptoms or
impacts on the patient.
Neurological assessments
Neurophysiology. The assessment and progression of neuro-
pathic symptoms in patients diagnosed with ATTRv amyloid-
osis can be assessed using multiple tools and scoring scales
that include the polyneuropathy disability (PND) score; neur-
opathy symptom score; Neurologic Disability Score (NDS);
total NIS and NIS-LL, each with their own advantages in
measuring disease progression [2].
The PND score is a simple staging system that provides a
good indication of disease staging, by categorizing patients
into four stages according to their neuropathy impairment
and its impact on ambulation: stage I (sensory disturbances
but with preserved walking capability); stage II (impaired
walking ability without need for a stick); stage III (walking
only with the help of one stick (IIIA) or two sticks (IIIB))
and stage IV (wheelchair- or bed-bound) [23].
An important neurological assessment to quantify neur-
opathy progression across the full disease course is total
NIS. NIS is a composite score derived from neurological
assessment of muscle strength, reflexes and sensation in the
upper and lower limbs [24]. It has been found to be posi-
tively associated with functional scales of locomotion, PND
Table 1. Spectrum of clinical findings at disease onset in hereditary variant ATTR amyloidosis genotype/phenotype groups.
Val30Met early onset (<50 years)
Val30Met late onset (>50 years)/
Non-Val30Met mixed phenotype
Non-Val30Met cardiac phenotype (onset >65 years)





 Cardiac conduction disturbances
 Gastrointestinal dysfunction
 Ophthalmopathy: dry eye/vitreous
opacities/secondary amyloid glaucoma
 Sensory and motor neuropathy
 Subtle autonomic signs
 Cardiomyopathy
 Cardiac conduction disturbances
 Ophthalmopathy: dry eye/vitreous opacities/
secondary amyloid glaucoma (more rarely)
 Bilateral carpal tunnel syndrome
 Symptoms associated with heart failure with preserved
or mildly depressed ejection fraction – no cavity
enlargement and symmetrical increase in wall thickness
 Cardiac conduction disturbances
 Disproportionately elevated NT-proBNP
 Relatively high frequency of bilateral carpal
tunnel syndrome
Renal involvement has been described in a sub-group of Portuguese patients with intermediate
onset and female predominance
Neuropathy and/or dysautonomia is rarely
present, in contrast to other genetic variants
Diagnosis <2 years from symptom onset
in endemic regions
Diagnosis >2 years from symptom onset in
non-endemic regions
Patients have a prognosis of only 2.5–5 years’
survival from disease onset
NT-proBNP: N-terminal pro-brain natriuretic peptide.
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score and disease stage [10]. Despite the “ceiling effect”
observed when measuring NIS in diagnosed and treated
patients with ATTRv amyloidosis, it remains a useful test
that should be considered to monitor disease progression,
until there are no further changes in value and the “ceiling”
has been reached.
Nerve conduction studies (NCS) and electromyography
(EMG) are good tools for longitudinal follow-up and assess-
ment of change from baseline for phenotypes associated with
sensorimotor polyneuropathy, although they are not sensitive
methods for small-fibre involvement [25]. With NCS, sensory
nerve action potentials (SNAP) and compound muscle action
potentials (CMAP) can be usefully measured and monitored,
being a direct measure of axonal loss [26].
Distal small-fibre neuropathy causes length-dependent
involvement of both somatic and autonomic unmyelinated
fibres. Electrochemical skin conductance (ESC), as measured
by SudoscanTM (Impeto Medical SAS, Paris, France), sympa-
thetic skin response (SSR) and quantitative sudomotor axon
reflex test (QSART) are the sudomotor tests most frequently
used for assessment of small unmyelinated fibres (C-fibres).
Quantitative sensory testing (QST) and laser-evoked poten-
tials (LEPs) also enable the assessment of small myelinated
(Ad fibres) and unmyelinated (C-fibres) fibres [26].
From the above tests, some are available in only a few
centres and are not suitable for a routine follow-up of
patients with ATTRv amyloidosis. QST is a psychophysical
test of sensory perception for longitudinal follow-up; how-
ever, it suffers from variability of instruments and methodo-
logical approaches for location, stimulus application and the
sensation qualities examined, making its reliability question-
able [26]. QSART provides a quantitative, validated assess-
ment of post-ganglionic sympathetic cholinergic sudomotor
function [26], although it can be time-consuming and com-
plex method for routine clinical application, requiring a
high degree of technical expertise, and is available in only a
limited number of centres [25]. SSR and LEP have a low
sensitivity and reach a rapid floor effect reflecting their lim-
ited use [25,27]. In a recent study, SSR failed to demonstrate
a significant decline over time [28].
ESC measured by Sudoscan as a non-invasive, quick and
reproducible test seems to be a good tool to evaluate the
progression of small-fibre function impairment and a prom-
ising tool to monitor disease progression, but may be lim-
ited in its use in more advanced stages of disease due to a
potential floor effect [25,28,29].
Although the above-mentioned neurophysiological tests
can be promising tools to follow-up disease progression, due
to the limitations described, the group agreed that, in rou-
tine clinical practice, a composite nerve conduction score
comprising a sensory score and a motor score could be a
useful and pragmatic tool. For the sensory score, SNAP can
provide unilateral assessment of the sural plus ulnar nerves.
For the motor score, CMAP can be used for the unilateral
assessment of the ulnar plus peroneal nerves. From a neuro-
physiological perspective, an overall approach for routine
clinical practice may therefore comprise a composite nerve
conduction score plus the use of Sudoscan.
Confocal microscopy for small-fibre nerve assessment. In
vivo confocal microscopy (IVCM) of the corneal nerves is
useful for both early detection and assessment of progres-
sion of small-fibre neuropathies [26,30]. It is a simple, rapid,
non-invasive, reiterative and cost-effective approach for
quantifying small-nerve fibre loss [31], making it suitable
for ongoing follow-up. Normative reference values are avail-
able [32], although there is great variability and standard
deviations are wide, even within age and sex classes. Thus,
with available analytic tools, it may still be difficult to use
IVCM as a routine diagnostic test. However, with a baseline
recorded, it may be useful for ongoing assessment of change
in an already diagnosed patient [33]. It seems to provide
sensitive results, as it may be altered in patients with asymp-
tomatic small-fibre polyneuropathy [31], and also allows
demonstration of re-innervation [34].
Some preliminary results in ATTRv amyloidosis have
shown that corneal fibre length, assessed using IVCM, was
correlated with clinical and paraclinical parameters of sen-
sorimotor and autonomic neuropathy, as well as functional
impairment stage [35]. Reliable automated analysis of IVCM
scans using software integrated into IVCM machines will
help to develop this non-invasive and rapid technology [36].
Altogether, IVCM represents a promising approach that
may be useful for monitoring patients with ATTRv amyloid-
osis, once data from longitudinal studies to assess the cap-
acity of IVCM to detect changes in corneal nerve fibre
length over time are available [35].
Exploratory neurological assessments
Magnetic resonance imaging. Less frequently used and
described in the literature, magnetic resonance neurography
is magnetic resonance imaging dedicated to the peripheral
nerves. It detects and localizes nerve injury at the level of
individual nerve fascicles [37]. Although in early stages of
use for monitoring disease progression, this imaging modal-
ity has been shown to detect and quantify lower limb nerve
injury in vivo at the microstructural level in patients with
symptomatic ATTR-PN, as well as in asymptomatic carriers
of a TTR mutation. It thus has potential for early monitor-
ing of microstructural nerve injury [37].
Skin biopsy. Skin biopsy can lead to a reliable quantification
of somatic and autonomic small nerve fibres using both
bright-field immunohistochemistry and indirect immuno-
fluorescence approaches. Intraepidermal nerve fibre density
is a consistent and stable measure [27], making it useful for
assessing disease progression when compared with a base-
line assessment. Skin biopsy is more accurate than nerve
biopsy, although may be limited in clinical practice owing
to logistical aspects and degree of availability.
Cardiac-specific assessments
Cardiac assessments should include clinical examination
using the New York Heart Association (NYHA) staging
system, electrocardiography (ECG), echocardiography, the
6-minute walk test (6MWT) and laboratory tests, such as
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N-terminal pro-hormone brain natriuretic peptide (NT-
proBNP), in each case.
NYHA functional class and NT-proBNP plasmatic con-
centration remain the most useful measures to longitudin-
ally monitor disease progression and should be repeated
every 6–8months in stable patients. Changes in the overall
functional capacity can also be accurately evaluated by
6MWT (as documented in the ATTR-ACT trial) [38].
A 12-lead ECG to detect rhythm, QRS duration, QRS
voltage, cQT, Q waves and ST abnormalities should be
repeated on at least an annual basis. An annual Holter
ECG should be used to search for rhythm and conduction
disturbances and for the assessment of heart rate variabil-
ity (in selected cases). The most relevant clinical implica-
tions are associated with the possible appearance of
paroxysmal atrial fibrillation or advanced atrioventricular
block. Echocardiography plays a major role in the non-
invasive diagnosis of cardiac amyloidosis due to its assess-
ment of structure and function. Myocardial thickness,
biventricular systolic and diastolic circumferential and
longitudinal function, parietal strain and strain rate can
be easily evaluated at basal level and during follow-up.
Nevertheless, variations in clinical status are rarely paral-
leled by changes in myocardial thickness. A restrictive
transmitral Doppler pattern is a marker of disease sever-
ity, and its disappearance can be considered as a sign of
haemodynamic improvement. Left ventricular (LV) ejec-
tion fraction is not a reliable marker of disease progres-
sion or regression in ATTR-CM. A recent prospective
trial using tafamidis indicated that changes in LV strain
measurements can parallel clinical improvements [38].
In a separate clinical trial using patisiran, improvements
were observed in cardiac manifestations of ATTRv amyl-
oidosis, as measured by LV strain, in a prespecified car-
diac subpopulation with mixed phenotype [19].
Cardiac magnetic resonance (CMR) can provide detailed
functional and morphological information. The advantage
of CMR is its unique ability to enable tissue characterisa-
tion through the extension of late gadolinium enhancement
on late gadolinium imaging and elevated native T1 and
extracellular volume (ECV). T1 mapping, a relatively new
and quantitative technique, with native T1 and ECV, has
the potential to longitudinally monitor disease progression
[39]. Nevertheless, the real possibility of CMR to assess the
response to disease modifying treatments remains to be
established.
Although myocardial scintigraphy with bone avid tracers
has high sensitivity and specificity for ATTR-CM, even in
cases with initial involvement, its capability of assessing longi-
tudinal changes in amyloid burden has not been demonstrated
[40]. New amyloid-specific positron-emission tomography
tracers are interesting but not yet accurately studied for evalu-
ating amyloid burden and longitudinal changes.
Ophthalmological assessment
Ocular manifestations of ATTRv amyloidosis are common,
some of them potentially blinding, and mainly include kera-
toconjunctivitis sicca, secondary glaucoma, vitreous deposits
and retinal angiopathy [4,41]. Ophthalmological examin-
ation, including best-corrected visual acuity, intraocular
pressure, slit lamp examination (including fluorescein stain-
ing of the ocular surface) and dilated fundus examination,
should be performed to assess dry eye, anterior and poster-
ior chamber amyloid deposits, as well as amyloid retinal
angiopathy [4,41]. Vitreous opacities should be monitored
using fundus photography and classified according to the
modified Koga classification [42]. Structural and functional
assessment of the optic nerve, by the measurement of the
retinal nerve fibre layer using optical coherence tomography
and automated visual field, should be performed in case of
elevated and/or significant increase in intraocular pressure.
Fluorescein angiography should be performed in case of
retinal haemorrhages suggestive of amyloid retinal angiop-
athy [42].
Renal assessment
Monitoring of renal function (serum creatinine, glomerular
filtration rate, proteinuria/microalbuminuria) is important,
as kidney impairment and proteinuria are clinical features
of ATTRv amyloidosis [43]. Microalbuminuria can precede
the onset of neuropathy [43] and therefore may be a useful
parameter to assess in the early stages of disease.
Among Portuguese patients with the Val30Met TTR muta-
tion, a subgroup was identified with renal disease character-
ized by early microalbuminuria turning into proteinuria and
progressive renal failure [44]. Following the onset of neur-
opathy, dialysis is generally required within 10 years [43].
Other assessments
Another useful assessment to detect disease progression
includes the measurement of body mass index (BMI).
Gastrointestinal symptoms are common in patients with
ATTRv amyloidosis and have a significant negative impact
on their nutritional status and health-related quality of life
[45]. The modified BMI, in which the BMI (kg/m2) is
multiplied by serum albumin (g/L) to compensate for pos-
sible oedema, appears to be well suited to monitoring dis-
ease progress [46]. Grip strength tests, for which normal
values by age and gender are available [47], are also simple
and useful in ongoing assessment and may be a good indi-
cator of change over time.
Strategy for clinical practice
Considering the usefulness of the various tools available to
assess disease progression in patients with ATTRv amyloid-
osis, we propose a structured follow-up tailored to individ-
ual patients, using tests and investigations dependent on the
genotype/phenotype of the individual (Tables 2 and 3). The
proposed structure aims to provide a personalized approach
to monitoring and management of the disease. It is import-
ant to note, however, that a necessary amount of time on
treatment is needed before benefit on disease can be seen
and this should be considered before adjusting the patient’s
treatment regime [48].
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Identifying the thresholds that indicate disease progres-
sion in treated patients with ATTRv amyloidosis
Using the suggested clinical indicators of change, the group
discussed potential thresholds that could indicate significant
disease progression with an associated need for consider-
ation of change in therapeutic and clinical intervention. It
was emphasized that detailed dialogue with each patient is a
crucial component of understanding change and the impact
of specific aspects of disease progression on the individual.
Standardizing any approach is challenging due to the clear
evidence that not all TTR variants will produce the same
pattern and course of disease, including rate of progression.
In addition, it is unlikely that the progression of the different
clinical factors will be linear, making the time since the onset
of disease another confounding factor. The specific mutation
and resulting patient phenotype are therefore an important
consideration in our conclusions.
Treatments are available for the management of ATTRv
amyloidosis and, as such, the group suggested useful thresh-
olds for change which could be indicative of significant dis-
ease progression. (Table 4). This is increasingly important
with the availability of more treatment choices and the need
Table 2. Useful assessments to assess disease progression in diagnosed and treated patient with neuropathic or mixed phenotype of hereditary variant ATTR
amyloidosis.
Val30Met early onset (<50 years)
Val30Met late onset (>50 years) /
Non-Val30Met mixed phenotype
Patient-reported questionnaires (yearly)  SIQ/SFN
 COMPASS-31 (autonomic symptom score)
 Norfolk QoL-DN
 Same as early onset, with increased emphasis on sensory and
motor impact
 Modified Norris test




 Same as early onset, with increased emphasis on physical impact
 Grip test
 6MWT
Neurophysiology (yearly)  Composite Nerve Conduction Score
 Sudoscan
Heart (6-monthly in cases of dysfunction)  ECG/Holter
 ECHO
 Additional involvement of cardiological assessments
for “cardiac” phenotypes
Kidney/laboratory (6-monthly)  Proteinuria
 Albuminuria/microalbuminuria




Eye (yearly in Val30Met and
3- to 6-monthly if pathologies present)
 Dry eye/glaucoma/vitreous opacities
 Confocal microscopy (needs further validation)
6MWT: 6-minute walk test; BP: blood pressure; CMAP: compound muscle action potential; ECG: electrocardiography; ECHO: echocardiography; NIS: Neuropathy
Impairment Score; NT-proBNP: N-terminal pro-brain natriuretic peptide; Norfolk QoL-DN: Norfolk Quality of Life-Diabetic Neuropathy; PND: polyneuropathy dis-
ability; SFN: small-fibre neuropathy; SIQ: Symptoms Inventory Questionnaire; SNAP: sensory nerve action potential.
Table 3. Useful assessments to assess disease progression in diagnosed and treated patients with cardiac phenotype of hereditary variant ATTR amyloidosis.
Non-Val30Met cardiac phenotype (>65 years)
For example Val122Ile, Leu111Met, Leu58His, Thr60Ala
Frequency of assessments  Stable patient – twice per year
 Rapidly progressing patient – at least every 2 months (for supportive treatment)
Clinical  mBMI
 Heart rate
 Blood pressure (including orthostatic)
 Jugular venous pressure
 Assess for cardiac murmurs and diastolic tones
 Assess for pulmonary congestion and pleural effusion
ECG  12-lead ECG (rhythm, QRS duration, QRS voltage, cQT, Q wave and ST-T abnormalities)
 Holter ECG aimed at searching for atrial fibrillation or conduction disturbances (if sinus rhythm on standard ECG)
every 6 months
ECHO  2D, M-mode Doppler ECHO: standard measurements (IVS and LPW thickness, LV diameters and volumes, LVEF, SV,
CO, LV myocardial fraction), TAPSE, estimated RV systolic pressure, estimated RA pressure, S wave on TDI, E/E’,
search for restrictive LV filling pattern, longitudinal strain and strain rate, semiquantitative or quantitative
evaluation of MI and TR, pericardial effusion (Y/N and degree), pleural effusion
 X-ray in selected cases
Laboratory  NT-proBNP
 Troponin
 Serum creatinine/calculated glomerular filtration rate
 Haemoglobin
Cardiovascular magnetic resonance  At least once (in selected cases it can be repeated)
 Not yet validated to evaluate the response to disease-modifying treatment
2D: two dimensional; BMI: body mass index; CO: cardiac output; ECG: electrocardiography; ECHO: echocardiography; IVS: interventricular septum; LPW: left pos-
terior wall; LV: left ventricular; LVEF: left ventricular ejection fraction; mBMI: modified body mass index; MI: mitral incompetence; NT-proBNP: N-terminal pro-
brain natriuretic peptide; RA: right atrial; RV: right ventricular; SV: stroke volume; TAPSE: tricuspid annular plane systolic excursion; TDI: tissue Doppler imaging;
TR: tricuspid regurgitation; Y/N: yes/no.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































to consider the necessary time required for the therapy to
demonstrate benefit for the patient before adjusting the
treatment regime. Interventions can therefore be targeted
and altered at the appropriate point in disease progression.
Newer treatment options are still to determine the time
required to show benefit; however, data for tafamidis have
shown that at least 1 year of administration is needed before
a benefit to disease can be seen [48], with greater efficacy
when administered early in the disease course [9,49]. In the
ATTR-ACT trial, the effect on overall survival in patients
with ATTR-CM emerged after approximately 18 months of
treatment with tafamidis [38], suggesting a possible longer
time to benefit for cardiac endpoints. This is likely owing to
ventricular remodeling, which can take months to achieve.
These findings would encourage continuing treatment with
tafamidis until at least after these timepoints.
Conclusions
A structured and personalized approach to the monitoring
of patients with ATTRv amyloidosis is needed, with ongoing
and frequent assessment of treated patients to inform man-
agement decisions. No validated approach to such monitor-
ing has been developed to date, and new techniques and a
combination of tests (composite scores) need to be incorpo-
rated into routine clinical practice. This paper is an initial
attempt in this direction, based on clinical experience and
emerging evidence and data.
When considering a structured approach, different pheno-
typical groups may be usefully recognized to address each
with specific tests and investigations, suggesting a more indi-
vidualized approach dependent on the specific TTR mutation
involved. This paper suggests that, in routine clinical practice,
it may be useful to consider patients within the following
categories: Val30Met early onset (<50 years), Val30Met late
onset (>50 years) and non-Val30Met mixed phenotype, and
non-Val30Met cardiac phenotype.
Multiple organ systems need to be assessed through a col-
laborative and multidisciplinary approach, including the assess-
ment of the nerves, heart, eyes and kidneys, as well as patient-
reported symptoms and health-related quality of life as eval-
uated from self-reported questionnaires, such as Norfolk QOL-
DN and COMPASS-31. Magnetic resonance neurography is
also a promising diagnostic and follow-up tool for the future.
The proposed approach should ensure structured, appro-
priate and ongoing assessment of individual patients being
treated for ATTRv amyloidosis, such that interventions can
be targeted and adjusted at the appropriate point in disease
progression. It should also help healthcare professionals to
consider the necessary time for individual therapies to dem-
onstrate benefit to the patient initiated on treatment, before
adjusting their treatment regime.
Disclosure statement
T. Coelho received financial support from Alnylam Pharmaceuticals,
IONIS Pharmaceuticals, and Pfizer, and serves on the THAOS scien-
tific advisory board.
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